1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Lamotrigine |
| brand | String | Lamictal (IR), Lamictal XR, Lamictal ODT |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Anticonvulsants|Anticonvulsant]] • [[:Category:Mood stabilizers|Mood stabilizer]] • [[:Category:Sodium channel blockers|Sodium channel blocker]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"' |
| starting_dose | String | |
| preparations | String | IR tablets 25, 100, 150, 200 mg; chewable dispersible tablets 2, 5, 25 mg; ODT 25, 50, 100, 200 mg; XR tablets 25, 50, 100, 200, 250, 300 mg |
| fda_max | String | 400 mg/day (bipolar monotherapy); 700 mg/day (epilepsy with enzyme-inducing comedication) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Antiepileptic effect within days at therapeutic level; mood-stabilizing effect emerges over weeks |
| duration | String | 24 hours (often divided BID at higher doses) |
| halflife | String | ~25-33 hours alone; ~15 hours with enzyme inducers; '''≥60 hours with valproate''' (UGT inhibition)'"`UNIQ--ref-00000025-QINU`"' |
| bioavailability | String | ~98% (oral)'"`UNIQ--ref-00000026-QINU`"' |
| pregnancy | String | '''Among the safest mood stabilizers in pregnancy''' with reassuring monotherapy registry data, in sharp contrast to valproate. Estrogen-containing contraceptives accelerate lamotrigine metabolism, requiring dose adjustments at start and stop of contraception'"`UNIQ--ref-00000027-QINU`"' |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US. Carries the FDA '''Boxed Warning for serious skin reactions''' including Stevens-Johnson syndrome and toxic epidermal necrolysis, with the risk concentrated in the first 2-8 weeks of therapy and elevated by rapid titration'"`UNIQ--ref-00000028-QINU`"' |
